1. Home
  2. VCIG vs BGLC Comparison

VCIG vs BGLC Comparison

Compare VCIG & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

SELL

Current Price

$9.20

Market Cap

12.5M

ML Signal

SELL

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.67

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VCIG
BGLC
Founded
2013
2017
Country
Malaysia
Malaysia
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
10.1M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
VCIG
BGLC
Price
$9.20
$2.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.0M
11.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.78
EPS
N/A
N/A
Revenue
N/A
$9,510,646.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.23
52 Week High
$15.45
$15.19

Technical Indicators

Market Signals
Indicator
VCIG
BGLC
Relative Strength Index (RSI) 96.34 51.64
Support Level $0.75 $2.58
Resistance Level $15.45 $3.07
Average True Range (ATR) 0.25 0.13
MACD 0.57 0.11
Stochastic Oscillator 82.08 92.59

Price Performance

Historical Comparison
VCIG
BGLC

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: